Triple Negative Breast Cancer
-
DATROWAY® Shows Unprecedented Five-Month Median Overall Survival Benefit vs. Chemotherapy in First-Line Treatment of Metastatic Triple-Negative Breast Cancer (TROPION-Breast02) for Patients Ineligible for Immunotherapy
The TROPION-Breast02 phase 3 trial, presented at ESMO 2025, shows DATROWAY significantly improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy in locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) patients ineligible for immunotherapy. DATROWAY reduced the risk of disease progression or death by 43% and improved median OS by 5 months. The objective response rate was 62.5% with DATROWAY versus 29.3% with chemotherapy, and median duration of response was 12.3 versus 7.1 months, respectively.
